The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection.
Kinin is an important mediator of hyperalgesia, inflammatory conditions and asthma. It causes pain, inflammation, increased vascular permeability and vasodilatation. Several kinin antagonists have been developed with the aim of treating these pathologies. Kinin B2 receptor agonists and kallikrein may have clinical utility in the treatment of hypertension, left ventricular hypertrophy, ischemic heart disease, congestive heart failure and diabetes. However, there is a need to know whether there is a safe therapeutic window between potential cardio-protective and pro-inflammatory effects following administration of kinin B2 receptor agonists.
Sharma
Jagdish N
JN
Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Centre, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait. j.n.sharma@hsc.edu.kw
D000818:Animals; D002318:Cardiovascular Diseases / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D007249:Inflammation / Q000503:physiopathology* / Q000517:prevention & control; D016234:Kallikrein-Kinin System / Q000187:drug effects / Q000502:physiology*; D007705:Kinins / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D043782:Receptor, Bradykinin B2 / Q000819:agonists / Q000502:physiology
D007705:Kinins; D043782:Receptor, Bradykinin B2